

Cite this: *Chem. Sci.*, 2018, 9, 336

# Scalable thioarylation of unprotected peptides and biomolecules under Ni/photoredox catalysis†

Brandon A. Vara,  Xingpin Li,  Simon Berritt,  Christopher R. Walters,   
E. James Petersson  and Gary A. Molander \*

Site-specific functionalization of unprotected native peptides and biomolecules remains a useful transformation in synthetic design and chemical biology, yet until recently, advancements in transition metal-catalyzed methods, which have prevailed in organic synthesis, have been relatively ineffective when applied to large and structurally complex biomolecules. Here, the mechanistically distinct, Ni/photoredox-catalyzed arylation of unprotected, native thiols (e.g., cysteine residues) is reported – a process initiated through a visible light-promoted, hydrogen atom transfer (HAT) event under ambient conditions. Sub-stoichiometric loadings of the dual-catalyst system ( $\leq 5$  mol%) are employed, granting excellent site-specificity, broad substrate scope, and low chemical waste. Reaction scalability (from  $\mu\text{g}$  to grams) has been achieved through modest reagent adjustments, and high throughput experimentation (HTE) demonstrates the ease of reaction setup, enabling prompt screening of aryl halide coupling partners and conditions. Scores of thiol substrates and aryl entities were examined and effectively conjugated, suggesting further diverse, practical applications.

Received 2nd October 2017  
Accepted 4th November 2017

DOI: 10.1039/c7sc04292b

rsc.li/chemical-science

## Introduction

Transition metal-catalyzed cross-couplings are an undisputable staple in synthetic chemistry, yet granting widespread substrate and functional group tolerance to such a critical class of reactions remains an overarching goal of much synthetic effort. Prominent among these are carbon–carbon and carbon–heteroatom (primarily O, N, and S) bond-forming reactions, which use (pro)nucleophilic species primed for transmetalation largely following historically similar, ionic (two-electron) mechanistic cycles in the presence of base. Within these classical paradigms, protecting group chemistry may be required when designing multi-step syntheses for complex molecules, especially peptides and other biomolecules, resulting in increased waste and poor chemical and step economy.<sup>1</sup> Consequently, efficient cross-coupling reactions conducted on natural, unmodified biological substrates remain scarce.<sup>2,3</sup> By contrast, a Ni/photoredox dual-catalyzed cross-coupling event driven by an overall redox-neutral process initiated by photon absorption (*via* focused visible light) can be employed within complex systems, orchestrated by catalytic amounts of photosensitizers and the selective pairing of single electron oxidation and reduction potentials with targeted reagents. As encouraging as the burgeoning field of radical photoredox chemistry has been, a mild and catalytic cross-coupling protocol in concert

with native, unprotected biomolecules through a single electron transfer (SET) manifold has yet to be realized.

Cysteine (Cys) sulfhydryl (R–SH) moieties are critical handles for chemical manipulation in bioconjugations, native chemical ligation, and peptide chemistry broadly, primarily because of the high relative nucleophilicity of sulfur and its low natural abundance in peptides and proteins.<sup>4</sup> For example, nonmetal-catalyzed Michael reactions and maleimide conjugations *via* reactive thiolate intermediates predominate, even when considering that the resulting thioether (Csp<sup>3</sup>–S) linkages can be labile and chemically reversible (*via* retro-Michael reactions) in physiological or basic environments.<sup>5</sup> This may be particularly problematic when designing clinical antibody–drug conjugates<sup>6</sup> or biological probes. Radical photo-crosslinking<sup>7</sup> of biological thiols and related open-shell transformations are well documented,<sup>8</sup> but incorporation of small molecules outside of thiol–ene/yne chemistry remain under-studied.<sup>9</sup> Accessing more resilient, irreversible aryl sulfide linkages [Csp<sup>2</sup>–S] from peptidic alkyl sulfhydryl groups presents a challenging, yet desirable, opportunity in synthetic cross-coupling chemistry to introduce a vast range of functional, aromatic small molecules.<sup>10</sup> The myriad protic, Lewis basic, and thiol functional groups inherent to native biomolecules have notoriously complicated applications of transition metal catalysis,<sup>11</sup> leading to catalyst deactivation, undesired cross reactivity, and complex reaction mixtures. Given these challenges, a reaction of practical significance would require mild, aqueous, and dilute reaction conditions near neutral pH (pH 6–8), favorable reaction kinetics, and highly chemoselective reagents without production of excessive waste.

Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, USA.  
E-mail: gmolandr@sas.upenn.edu

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc04292b







Fig. 1 Proposed Ni/photoredox catalytic cycle and thioarylation reaction scheme. (A) Catalytic cycle is initiated by photon absorption, generating excited state Ru photocatalyst, followed by oxidation of the HAT reagent via SET. Rapid H-atom abstraction from the sulfhydryl group generates a thiyl radical, which adds to Ni(0). This is followed by Ni(II) oxidative addition<sup>23</sup> with the requisite aryl bromide. Reductive elimination from Ni(III) affords the desired thioarylated biomolecule, and the dual catalytic cycles are closed by a final SET. (B) Ni/photoredox thioarylation reaction with GSH (**1**) and **2** affords the arylated peptide. Select experiments are outlined that deviate from the general conditions. Additional experiments and the structure of 4CzIPN can be found in the ESI†

## Examination of aryl halides

In addition to showcasing broad functional group/substrate tolerance, a secondary focus was to incorporate bio-relevant handles for additional chemical and/or bioconjugation strategies. Two distinct thiols, in addition to GSH, were surveyed with various aryl bromides to probe the scope of this transformation – chiral, racemic secondary thiol, tiopronin, a marketed pharmaceutical for the treatment of urologic cystinuria, and a trifunctional, tertiary alkyl thiol, D-penicillamine,<sup>24</sup> which is used in treatments for Wilson's disease and as a precursor to  $\beta$ -lactam antibiotics and other pharmaceuticals (Chart 1). The inclusion of unnatural or modified amino acids is a validated technique to improve peptide or peptide–drug conjugate properties such as potency or bioavailability, as well as to decelerate metabolism.<sup>25</sup>

Isolated yields reported herein (Chart 1) were enabled by high throughput experimentation and purification *via* mass/UV-directed reverse phase preparatory liquid chromatography

(prep-LC) and optimized for purity. Thus, yields do not necessarily reflect accurate conversion to product (see ESI† for details). Additionally, over the course of these studies, it proved prudent to examine workup and purification strategies carefully, as isolation of polar small molecules and peptides can be challenging, particularly on larger scales (>5  $\mu\text{mol}$ ). Undesired organic byproducts from the crude thioarylation reaction mixture (catechol, unreacted aryl bromide, and importantly, DMF) could be removed into the organic media *via* extraction from water using  $\text{CH}_2\text{Cl}_2$  when GSH (**1**) or D-penicillamine (**8**) were employed as starting materials. Moreover, select polar or amphoteric aryl sulfide adducts were agreeably found to precipitate from the aqueous solution following extraction, and the solids could be washed and vacuum filtered (see ESI† for details).

Cys-containing glutathione **1** was examined with an array of (hetero)aryl bromides under general conditions. Various unmasked functional handles were tolerated in both the *para*



and *meta* positions of bromoarenes, including acids (**1b**, **1i**), benzamide (**1c**), sulfonamide (**1d**), ketone (**1e**), and phenol (**1h**), and the resulting aryl sulfide adducts were isolated in moderate to good yields (1° alkyl thiols, Chart 1). Electron-rich arenes (**1f**) were employed as well, albeit providing lower isolated yields. The aryl bromide bearing an azide was not compatible with this SET chemistry, and activated olefins<sup>26</sup> yielded a mixture of compounds.

Aromatics bearing tethered primary alcohols (**1f**, **1j**, **1l** and **1m**, Chart 1), which resemble aryl PEG linkers, as well as a primary chloride (**1o**) were selectively linked with GSH (56%, 37%, and 35% yield, respectively). Notably, displacement of the primary chloride was not observed under the mild reaction conditions. Remarkably, free boronic acids were incorporated

and isolated in excellent yields (**1k**, **1n**; 46% and 83%, respectively) following a simple acid workup of the crude pinacol boronate (BPin) ester product. Boronic acids have shown unique function as covalent binders with *cis*-diols and cellular surface glycosides.<sup>27</sup> A pendant biotin derivative (**1q**), coumarin (**1p**), and unprotected glycoside (**1r**) were installed with excellent selectivity at sulfur in good yields (61%, 58%, and 40% yield, respectively). The conjugated coumarin adduct **1p** with an electron-donating sulfur atom in the 7-position is noteworthy, possessing an excitation maximum at 332 nm and emission maximum at 422 nm with a larger Stokes shift than the more common 7-methoxycoumarin.<sup>28</sup> Additionally, structurally complex, drug-like small molecules such as benzodiazepine **1s**, with potential applications in drug delivery,<sup>29</sup> and the basic



Chart 1 Ni/Photoredox thioarylation reaction and scope of various thiol and arene small molecules.  $\text{Bu}[\text{Si}^-]$  = diisopropylammonium bis(catechol)isobutylsilicate. DMF = *N,N*-dimethylformamide. Reactions conducted with 0.1 mmol thiol and ArBr, unless otherwise noted; isolated yields are reported (TFA salt omitted for clarity, see ESI<sup>†</sup> for additional details). <sup>a</sup> 0.12 mmol GSH employed. <sup>§</sup> 2 equiv. ArBr was employed. <sup>†</sup> The adduct was filtered following precipitation from the aqueous solution.





guanidine-containing thiophene **1t** were generated in synthetically useful yields (50% and 38%, respectively).

Thioarylation of the secondary thiol, tiopronin (**7**), proved quite broad when examined with various (hetero)aryl bromides. Hindered *ortho* substituents, as well as the unprotected, deoxyuridine-derived bromide (**7d**, 31%) and drug-like heteroaromatics (**7c** and **7g**, 56% and 66%, respectively) were incorporated. The tertiary thiol, D-penicillamine (**8**) progressed sluggishly in comparison to tiopronin and GSH, likely attributable to increased steric demand around sulfur and the more reversible nature of the thiol radical addition to the Ni metal center. In general, thiol homodimerization was more evident (5–15%) with increasing alkyl branching. Nonetheless, these hindered aryl sulfides were isolated in useful yields from tertiary thiol **8**, including unprotected nicotinamide derivative **8c** (48% yield, Chart 1), in contrast to the lack of similar reported compounds in Ni/photoredox-catalyzed heteroarylation (O–C<sup>30</sup> or N–C<sup>31</sup>) reactions.

### Microscale examination of diverse halides

In a final, comprehensive demonstration of aryl halide scope, the Ni/photoredox thioarylation protocol was examined *via* high-throughput experimentation (HTE) to evaluate 18 complex halides from a cross-coupling reaction informer set provided by

Merck Research Laboratories. Standardized reaction conditions [1 : 2 thiol/halide stoichiometry, 5 mol% Ni (**5**) and 2 mol% Ru (**6**)] were employed across a microscale informer plate, examining four distinct thiols, including a secondary thioglucose derivative, over 24 h on a bed of blue LEDs (Fig. 2A, B and Chart S1–4†). Gratifyingly, the majority of aryl halides showed reactivity ‘hits’ (aryl chlorides inactive) with the employed thiols, demonstrating the reaction’s tolerance to dynamic, drug-like aryl bromides, and in particular, aryl iodides (**X14**, **X15**; Fig. 2B).

However, in comparison to penicillamine and in contrast with previous findings, GSH provided uncharacteristically low success rates, likely because of solubility/stirring issues. This informer plate study reveals the potential of the developed thiol-conjugation platform to be a broad-spectrum Csp<sup>2</sup>–S cross-coupling reaction, providing a protocol that leads to reasonable conversions over a variety of complex thiol and aryl bromide partners.

Although an array of functionalized, brominated arenes were deemed compatible, studies were next conducted to gauge the tolerance of this SET thioarylation in the presence of challenging amino acid additives as a basis for applications in more complex peptide chemistry. Encouraged by the GSH results, efforts were focused on more challenging protic, basic, and polyfunctionalized amino acids and other biomolecules (Fig. 2C). The majority of biological small molecule additives




Fig. 2 Rapid exploration of Merck aryl halide informer plate *via* HTE and tolerability studies of biological additives under optimized conditions. (A) Merck halides run with 4 diverse thiols; reported numbers in cells present product area%/internal std area% (normalized). (B) Structures of successful Merck halides (**X1**–**X15**) as explored in A. (C) Biological additives (1 equiv., box a; 0.5 equiv., box b) were screened under optimized conditions; yield determined vs. internal standard (average of 2 runs).







adjustments, depending on the type (primary through tertiary alkyl thiols) or quantity ( $\mu\text{g}$  to grams) of thiol employed, and cysteine-containing polypeptides were selectively conjugated to various arenes in under 90 min in DMF (10 mM). Straightforward reaction set-up also permitted microscale high throughput experimentation (HTE) to screen optimal conditions and substrates in an effort to broaden the reach of this transformation in unprotected systems. Rapid screening of aryl halides and reaction scalability were largely enabled by an inexpensive, versatile, and bench-stable Ni precatalyst (5 mol% employed). The designed Ni/photoredox thioarylation reaction does not require transition-metal reagents, large excess of aryl halide (>20 equiv.), nor elaborate ligand design, and may well serve research communities interested in quickly accessing native, protected and/or unprotected, thioarylated small biomolecules, thus serving as a practical complement to Pd-catalyzed processes that have proven effective for protein bioconjugation.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

We thank Prof. David Chenoweth (University of Pennsylvania) for contributing discussions and David Primer (University of Pennsylvania) for preliminary informer plate reaction screens. We thank Dr Charles W. Ross, III (University of Pennsylvania) for mass spectral data, and Dr Jun Gu for NMR assistance and data collection. This work was funded by the National Institutes of Health (NIGMS 1 R01 GM113878 to G. A. M.) and in part by the National Science Foundation (NSF CHE-1708759 to E. J. P.). C. R. W. thanks the NIH for funding through the Structural Biology and Molecular Biophysics Training Program (T32 GM008275). We also thank NIH S10 OD011980 for mass-directed LCMS purification and related equipment.

## References

- 1 T. Newhouse, P. S. Baran and R. W. Hoffmann, *Chem. Soc. Rev.*, 2009, **38**, 3010–3021.
- 2 J. M. Antos and M. B. Francis, *Curr. Opin. Chem. Biol.*, 2006, **10**, 253–262.
- 3 E. Baslé, N. Joubert and M. Pucheault, *Chem. Biol.*, 2010, **17**, 213–227.
- 4 S. B. Gunnoo and A. Madder, *ChemBioChem*, 2016, **17**, 529–553.
- 5 S. C. Alley, D. R. Benjamin, S. C. Jeffrey, N. M. Okeley, D. L. Meyer, R. J. Sanderson and P. D. Senter, *Bioconjugate Chem.*, 2008, **19**, 759–765.
- 6 A. Beck, L. Goetsch, C. Dumontet and N. Corvaia, *Nat. Rev. Drug Discovery*, 2017, **16**, 315–337.
- 7 C. E. Hoyle and C. N. Bowman, *Angew. Chem., Int. Ed.*, 2010, **49**, 1540–1573.
- 8 S. Wittrock, T. Becker and H. Kunz, *Angew. Chem., Int. Ed.*, 2007, **46**, 5226–5230.
- 9 (a) Radical arylation of Tyr residues: S. K. Fehler, G. Pratsch, C. Östreicher, M. C. D. Fürst, M. Pischetsrieder and M. R. Heinrich, *Tetrahedron*, 2016, **72**, 7888–7893; (b) Photoredox arylation of glycine derivatives: S. Zhu and M. Rueping, *Chem. Commun.*, 2012, **48**, 11960–11962.
- 10 (a) C. Zhang, A. M. Spokoyny, Y. Zou, M. D. Simon and B. L. Pentelute, *Angew. Chem., Int. Ed.*, 2013, **52**, 14001–14005; (b) J. N. deGruyter, L. R. Malins and P. S. Baran, *Biochemistry*, 2017, **56**, 3863–3873.
- 11 C. C. Eichman and J. P. Stambuli, *Molecules*, 2011, **16**, 590–608.
- 12 (a) E. V. Vinogradova, A. M. Spokoyny, B. L. Pentelute and S. L. Buchwald, *Nature*, 2015, **526**, 687–691; (b) The use of catalytic Pd has been reported in the presence of protected peptides, although not in the context of thioarylation chemistry. Select examples include: A. J. Reay, L. A. Hammarback, J. T. W. Bray, T. Sheridan, D. Turnbull, A. C. Whitwood and I. J. S. Fairlamb, *ACS Catal.*, 2017, **7**, 5174–5179; (c) Y. Zhu, M. Bauer and L. Ackermann, *Chem. Commun.*, 2015, **21**, 9980–9983.
- 13 J. Willwacher, R. Raj, S. Mohammed and B. G. Davis, *J. Am. Chem. Soc.*, 2016, **138**, 8678–8681.
- 14 (a) T. Kondo and T.-A. Mitsudo, *Chem. Rev.*, 2000, **100**, 3205–3220; (b) C. Zong, J. Liu, S. Chen and R. Zeng, *Chin. J. Chem.*, 2014, **32**, 212–218.
- 15 N. Toda, S. Asano and C. F. Barbas, *Angew. Chem., Int. Ed.*, 2013, **52**, 12592–12596.
- 16 A. M. Spokoyny, Y. Zou, J. J. Ling, H. Yu, Y.-S. Lin and B. L. Pentelute, *J. Am. Chem. Soc.*, 2013, **135**, 5946–5949.
- 17 (a) E. Brachet, J.-D. Brion, M. Alami and S. Messaoudi, *Chem.-Eur. J.*, 2013, **19**, 15276–15280; (b) An arylated gold(III) complex has also been reported for cysteine arylations: K. K.-Y. Kung, H.-M. Ko, J.-F. Cui, H.-C. Chong, Y.-C. Leung and M.-K. Wong, *Chem. Commun.*, 2014, **50**, 11899–11902.
- 18 C. Bottecchia, M. Rubens, S. B. Gunnoo, V. Hessel, A. Madden and T. Noël, *Angew. Chem., Int. Ed.*, 2017, **56**, 12702–12707.
- 19 M. Jouffroy, C. B. Kelly and G. A. Molander, *Org. Lett.*, 2016, **18**, 876–879.
- 20 K. Lin, C. B. Kelly, M. Jouffroy and G. A. Molander, *Org. Synth.*, 2017, **94**, 16–33.
- 21 V. Corce, L.-M. Chamoreau, E. Derat, J.-P. Goddard, C. Ollivier and L. Fensterbank, *Angew. Chem., Int. Ed.*, 2015, **54**, 11414–11418.
- 22 F. Dénès, M. Pichowicz, G. Povie and P. Renaud, *Chem. Rev.*, 2014, **114**, 2587–2693.
- 23 Ni oxidative addition may also arise from a putative Ni(I) to Ni(III) cycle.
- 24 J. C. Crawhall, D. Lecavalier and P. Ryan, *Biopharm. Drug Dispos.*, 1979, **2**, 73–95.
- 25 L. Di, *AAPS J.*, 2014, **17**, 134–143.
- 26 Desired aryl sulfide adducts can still be isolated in these cases, albeit in much lower isolated yields (<15%) and were not extensively pursued for this report. Byproducts are primarily the dialkyl thioether isomers from thiol-ene/yne additions.





